CD274 and neoplasm: With these results, and other coming from exploratory analyses of some first-line phase III trials comparing CPIs in monotherapy or in combination with chemotherapy vs. chemotherapy alone, pembrolizumab and atezolizumab are currently approved by EMA as monotherapy in first-line for patients considered cisplatin ineligible whose tumors express PD-L1 (CPS score ≥ 10% or tumor PD-L1 expression 5% respectively).